Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Read more
FDA Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients Read more
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome Read more
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome Read more